DPYSL5 and small cell lung carcinoma: We may also predict the response to treatment based on the autoantibody class. We are presenting a very unusual case of two completely different paraneoplastic syndromes with two different autoantibodies, gamma-aminobutyric acid-B (GABA<sub>B</sub>) and collapsin response mediator protein 5 (CRMP5), in a patient with underlying small-cell lung cancer.